Key result
Recurrent MR ≥3+ affects ~10% of patients one year post-TEER, requiring specific management strategies.
Why the study?
Recurrent MR occurs in up to 10% of patients at 1 year after M-TEER, and subsequent altered valve anatomy complicates further treatment strategies.
This review outlines practical management strategies for the growing population of patients who develop residual or recurrent mitral regurgitation following transcatheter edge-to-edge repair.
Provides framework for managing recurrent MR post-M-TEER; leaves open prospective validation of algorithms.
Mitral valve transcatheter edge-to-edge repair (M-TEER) is an established treatment option for patients with severe mitral regurgitation (MR) at high risk for surgery. However, the rate of recurrent MR ≥ 3+ after M-TEER may be up to 10% at 1 year. As the volume of M-TEER procedures increases, the number of patients experiencing recurrent MR post-TEER is also rising. M-TEER reshapes valve anatomy and complicates further treatment strategies for MR. In this review, the authors provide practical management considerations for patients with residual or recurrent MR after M-TEER.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) conducted a review in Residual or recurrent mitral regurgitation after M-TEER. Management of residual or recurrent mitral regurgitation was evaluated. Recurrent mitral regurgitation ≥ 3+ after transcatheter edge-to-edge repair occurs in up to 10% of patients at 1 year, necessitating specific management strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: